🟢 AIM ImmunoTech is trading 10.78% up today after European and UK patent protection through 2041

AIM ImmunoTech is trading 10.78% up now at $0.26 after securing European and United Kingdom patent protection for Ampligen’s Long COVID use through June 2041.

• The protection spans major European markets and covers dosing and delivery methods, strengthening the company’s intellectual-property position.
• The European opposition period closed without opposition on August 25, 2026.
• Broader risk-on conditions and biotech strength may be supportive, but the patent milestone is the clearest catalyst.